首页> 外文OA文献 >Photocatalytic degradation of pharmaceuticals in aqueous solutions and development of new dye sensitised photocatalytic materials
【2h】

Photocatalytic degradation of pharmaceuticals in aqueous solutions and development of new dye sensitised photocatalytic materials

机译:光催化降解水溶液中的药物和开发新的染料敏化光催化材料

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

This research examines the photocatalytic degradation of 3 active pharmaceutical ingredients (APIs) Famotidine (FAM), Tamsulosin Hydrochloride (TAM) and Solifenacin Succinate (SOL) using TiO2 and UV light. Photocatalytic degradation studies were monitored with individual HPLC-PDA methods which were developed and validated. The optimum concentration of TiO2 to treat 0.32 L of 0.083 mM drug solution was found to be 0.1 g or 0.2 g, and all three pharmaceuticals could be appreciably degraded within the 3 hour irradiation period (100% FAM and TAM, and ~80 % of SOL). Various parameters were also investigated on the process such as pH, oxidant addition etc. pH was not found to significantly affect the photocatalytic degradation process, although there was notably more adsorption of the drug to the TiO2 surface at more alkaline pHs. This increase in adsorption of the drug at alkaline pH, in the case of SOL, did not lead to an enhanced photocatalytic degradation as is often reported by other authors.ududVarious intermediates (or degradation products) were observed in LC traces of photocatalytic studies and the addition of hydrogen peroxide to the TiO2/UV process was found to hinder the formation of these intermediates and eliminate them completely within the allotted irradiation time. Concentration studies examined the robustness of the proposed TiO2/UV process to varying concentrations of drug solution. These indicated that the process can completely eliminate concentrations up to 0.2 mM of FAM and TAM, and determined that in the case of SOL only low concentrations of drug can be completely eliminated (0.02 mM).ududThe intermediates of the optimised photocatalytic degradation experiments were analysed initially by DI-MS, allowing some initial intermediates being proposed. This data was later corroborated with LC-MS/MS data from photodegradation experiments and various intermediates were further proposed based on the masses and fragments obtained from this analysis. Including isomers, over 80 intermediates were discovered between the 3 APIs. Routes of degradation have also been postulated based on the intermediates proposed.ududFurther to this, composite materials based on TiO2 and dye molecules have been developed in the hope of developing solar/visible light activated photocatalysts. A visible light sensitised photocatalyst based on the porphyrin tetra-(4-carboxyphenyl)porphyrin was successfully developed. This composite was prepared by a simple adsorption method of preparation and was compared in activity to a harsher literature reflux method. Other composites based on novel metallated and metal free phthalocyanine dyes (MPc and Pc) were also prepared and characterised by UV spectroscopy (solution and solid-state) and FT-IR spectroscopy. The photoactivity of these composites was examined with our pharmaceutical targets. These are the first composite materials, to our knowledge, to be tested with actual pharmaceuticals. The porphyrin/TiO2 composite showed good photoactivity in the degradation of FAM, although LC traces indicated that this degradation could merely be a selective conversion to an oxidised/reduced form of FAM. Tests with the other pharmaceuticals further indicated this selectivity toward FAM, as no degradation occurred with either TAM or SOL. MPc/TiO2 and Pc/TiO2 composites were also tested with Famotidine, however these exhibited a poor/negligible degradation compared to the porphyrin/TiO2 composite.
机译:这项研究研究了使用TiO2和紫外光对3种活性药物成分(API)法莫替丁(FAM),盐酸坦洛新(TAM)和琥珀酸索非那新(SOL)的光催化降解。用已开发和验证的单个HPLC-PDA方法监测光催化降解研究。发现用于处理0.32 L的0.083 mM药物溶液的TiO2的最佳浓度为0.1 g或0.2 g,并且三种药物在3小时的照射时间内均会明显降解(100%FAM和TAM,约80%的FAM和TAM)。 SOL)。还对过程中的各种参数进行了研究,例如pH值,氧化剂的添加等。尽管在碱性更高的pH值下,药物对TiO2表面的吸附明显增加,但并未发现pH值会显着影响光催化降解过程。在SOL的情况下,这种在碱性pH值下药物吸附的增加并未导致其他作者经常报道的增强的光催化降解。 ud ud在LC痕量光催化中观察到各种中间体(或降解产物)研究发现,在TiO2 / UV工艺中添加过氧化氢会阻碍这些中间体的形成,并在指定的照射时间内完全消除它们。浓度研究检查了所提出的TiO2 / UV工艺对不同浓度药物溶液的鲁棒性。这些表明该过程可以完全消除浓度高达0.2 mM的FAM和TAM,并确定在SOL的情况下只能完全消除低浓度的药物(0.02 mM)。 ud ud优化的光催化降解中间体最初通过DI-MS对实验进行了分析,从而提出了一些初始中间体。后来,该数据与来自光降解实验的LC-MS / MS数据得到了证实,并根据从该分析中获得的质量和碎片进一步提出了各种中间体。包括异构体在内,在这三个原料药之间发现了80多种中间体。基于所提议的中间体,还推测出了降解途径。 ud ud此外,基于TiO 2和染料分子的复合材料已经被开发出来,以期希望开发太阳能/可见光活化的光催化剂。成功开发了基于卟啉四-(4-羧基苯基)卟啉的可见光敏光催化剂。通过简单的吸附制备方法制备该复合材料,并将其活性与较严格的文献回流方法进行比较。还制备了其他基于新型金属化和无金属酞菁染料(MPc和Pc)的复合材料,并通过紫外光谱(溶液和固态)和FT-IR光谱进行了表征。用我们的药物靶标检查了这些复合材料的光活性。据我们所知,这是第一种使用实际药物进行测试的复合材料。卟啉/ TiO2复合物在FAM的降解中显示出良好的光活性,尽管LC痕迹表明这种降解可能只是选择性转化为FAM的氧化/还原形式。对其他药物的测试进一步表明了对FAM的选择性,因为TAM或SOL均未发生降解。还使用法莫替丁对MPc / TiO2和Pc / TiO2复合材料进行了测试,但是与卟啉/ TiO2复合材料相比,它们的降解差/可忽略不计。

著录项

  • 作者

    Murphy Sharon;

  • 作者单位
  • 年度 2012
  • 总页数
  • 原文格式 PDF
  • 正文语种 en
  • 中图分类

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号